GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Classificação em ações
#3764
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Preço da ação
$25.74
Valor de mercado
$4.36B
Variação (1 dia)
-5.27%
Variação (1 ano)
-17.87%
País
IN
Negociar GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categoria
Healthcare
Receita da GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Receita em Jun 2026 TTM: $436.46M
De acordo com os últimos relatórios financeiros da GlaxoSmithKline Pharmaceuticals Limited, a receita atual da empresa (TTM) é $436.46M. Em 2024, a empresa obteve uma receita de $414.20M um aumento em relação a a receita do ano 2023, que foi de $395.68M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da GlaxoSmithKline Pharmaceuticals Limited de 2004 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $436.46M | -0.43% |
| 2025 | $438.37M | 5.84% |
| 2024 | $414.20M | 4.68% |
| 2023 | $395.68M | -8.37% |
| 2022 | $431.83M | 8.05% |
| 2021 | $399.65M | -6.62% |
| 2020 | $428.01M | -4.99% |
| 2019 | $450.48M | 2.15% |
| 2018 | $441.02M | -1.67% |
| 2017 | $448.50M | 4.70% |
| 2016 | $428.36M | 1.31% |
| 2015 | $422.83M | -0.90% |
| 2013 | $426.68M | -11.70% |
| 2012 | $483.21M | 7.85% |
| 2011 | $448.05M | -6.91% |
| 2010 | $481.30M | 17.28% |
| 2009 | $410.39M | 17.56% |
| 2008 | $349.09M | -14.58% |
| 2007 | $408.65M | 14.51% |
| 2006 | $356.86M | 5.90% |
| 2005 | $336.97M | 3.85% |
| 2004 | $324.46M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $79.67B | 18,152.62% |
US
|
|
| $99.34B | 22,659.12% |
US
|
|
| $64.39B | 14,651.79% |
US
|
|
| $66.40B | 15,113.23% |
US
|
|
| $77.52B | 17,660.65% |
CH
|
